| Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection EB Hirsch, VH Tam Journal of Antimicrobial Chemotherapy 65 (6), 1119-1125, 2010 | 741 | 2010 |
| International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical … BT Tsuji, JM Pogue, AP Zavascki, M Paul, GL Daikos, A Forrest, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 39 (1 …, 2019 | 692 | 2019 |
| Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes EB Hirsch, VH Tam Expert review of pharmacoeconomics & outcomes research 10 (4), 441-451, 2010 | 607 | 2010 |
| Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus RL Nation, J Li, O Cars, W Couet, MN Dudley, KS Kaye, JW Mouton, ... The Lancet infectious diseases 15 (2), 225-234, 2015 | 380 | 2015 |
| Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy N Jumbe, A Louie, R Leary, W Liu, MR Deziel, VH Tam, R Bachhawat, ... The Journal of clinical investigation 112 (2), 275-285, 2003 | 336 | 2003 |
| New β-lactam–β-lactamase inhibitor combinations D Yahav, CG Giske, A Grāmatniece, H Abodakpi, VH Tam, L Leibovici Clinical microbiology reviews 34 (1), 10.1128/cmr. 00115-20, 2020 | 334 | 2020 |
| Pharmacodynamics of cefepime in patients with Gram-negative infections VH Tam, PS McKinnon, RL Akins, MJ Rybak, GL Drusano Journal of Antimicrobial Chemotherapy 50 (3), 425-428, 2002 | 285 | 2002 |
| Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa VH Tam, AN Schilling, G Vo, S Kabbara, AL Kwa, NP Wiederhold, ... Antimicrobial agents and chemotherapy 49 (9), 3624-3630, 2005 | 256 | 2005 |
| Nebulized Colistin in the Treatment of Pneumonia Due to Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa ALH Kwa, CS Loh, JGH Low, A Kurup, VH Tam Clinical infectious diseases 41 (5), 754-757, 2005 | 246 | 2005 |
| Optimization of Meropenem Minimum Concentration/MIC Ratio To Suppress In Vitro Resistance of Pseudomonas aeruginosa VH Tam, AN Schilling, S Neshat, K Poole, DA Melnick, EA Coyle Antimicrobial agents and chemotherapy 49 (12), 4920-4927, 2005 | 236 | 2005 |
| Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity NP Wiederhold, DP Kontoyiannis, J Chi, RA Prince, VH Tam, RE Lewis The Journal of infectious diseases 190 (8), 1464-1471, 2004 | 230 | 2004 |
| Prevalence, Resistance Mechanisms, and Susceptibility of Multidrug-Resistant Bloodstream Isolates of Pseudomonas aeruginosa VH Tam, KT Chang, K Abdelraouf, CG Brioso, M Ameka, LA McCaskey, ... Antimicrobial agents and chemotherapy 54 (3), 1160-1164, 2010 | 225 | 2010 |
| Polymyxin B: similarities to and differences from colistin (polymyxin E) A Kwa, SK Kasiakou, VH Tam, ME Falagas Expert review of anti-infective therapy 5 (5), 811-821, 2007 | 218 | 2007 |
| Impact of Multidrug-Resistant Pseudomonas aeruginosa Bacteremia on Patient Outcomes VH Tam, CA Rogers, KT Chang, JS Weston, JP Caeiro, KW Garey Antimicrobial agents and chemotherapy 54 (9), 3717-3722, 2010 | 208 | 2010 |
| In Vitro Assessment and Multicenter Cohort Study of Comparative Nephrotoxicity Rates Associated with Colistimethate versus Polymyxin B Therapy K Phe, Y Lee, PM McDaneld, N Prasad, T Yin, DA Figueroa, WL Musick, ... Antimicrobial agents and chemotherapy 58 (5), 2740-2746, 2014 | 200 | 2014 |
| Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy PR Ingram, DC Lye, PA Tambyah, WP Goh, VH Tam, DA Fisher Journal of antimicrobial chemotherapy 62 (1), 168-171, 2008 | 199 | 2008 |
| Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence ME Falagas, IA Bliziotis, VH Tam International journal of antimicrobial agents 29 (1), 9-25, 2007 | 173 | 2007 |
| In Vitro Activity of MK-7655, a Novel β-Lactamase Inhibitor, in Combination with Imipenem against Carbapenem-Resistant Gram-Negative Bacteria EB Hirsch, KR Ledesma, KT Chang, MS Schwartz, MR Motyl, VH Tam Antimicrobial agents and chemotherapy 56 (7), 3753-3757, 2012 | 167 | 2012 |
| Surveillance and correlation of antibiotic prescription and resistance of Gram-negative bacteria in Singaporean hospitals LY Hsu, TY Tan, VH Tam, A Kwa, DA Fisher, TH Koh Antimicrobial agents and chemotherapy 54 (3), 1173-1178, 2010 | 164 | 2010 |
| Modelling time–kill studies to discern the pharmacodynamics of meropenem VH Tam, AN Schilling, M Nikolaou Journal of antimicrobial chemotherapy 55 (5), 699-706, 2005 | 160 | 2005 |
